What are the FRAX (Fracture Risk Assessment Tool) 10‑year major osteoporotic fracture and hip fracture probability thresholds for initiating osteoporosis treatment in patients aged 50 years or older (women versus men)?

FRAX Treatment Thresholds for Osteoporosis

For postmenopausal women and men aged 50 years or older, initiate osteoporosis treatment when the 10-year FRAX probability reaches ≥3% for hip fracture OR ≥20% for major osteoporotic fracture (clinical spine, hip, forearm, or humerus). 1, 2, 3, 4

Standard Treatment Thresholds (Identical for Both Sexes)

The National Osteoporosis Foundation established these intervention thresholds that apply equally to both postmenopausal women and men ≥50 years: 4, 5

• Hip fracture probability: ≥3% triggers treatment recommendation 1, 2, 3
• Major osteoporotic fracture probability: ≥20% triggers treatment recommendation 1, 2, 3

These thresholds are sex-neutral—the same cutoffs apply regardless of whether the patient is male or female. 4, 5

Risk Stratification Framework

Very High Risk (Immediate Treatment Indicated)

The following criteria mandate treatment consideration, superseding FRAX thresholds: 1

• Major osteoporotic fracture risk >30% 1, 3
• Hip fracture risk >4.5% 1, 3
• Recent fracture within the past 12 months 1
• Multiple fragility fractures 1
• T-score <-3.0 at hip or spine 1
• Fracture occurring while on osteoporosis therapy 1

High Risk (Strong Treatment Recommendation)

• Major osteoporotic fracture risk ≥20% 1, 2, 3
• Hip fracture risk ≥3% 1, 2, 3
• T-score ≤-2.5 at hip or spine in postmenopausal women or men ≥50 years 1, 6, 4
• Any prior osteoporotic fracture (regardless of FRAX score) 1, 6, 4

Moderate Risk (Conditional Treatment Recommendation)

• Major osteoporotic fracture risk 10-19% 1, 2, 3
• Hip fracture risk >1% and <3% 1, 2

Low Risk (Treatment Generally Not Indicated)

• Major osteoporotic fracture risk <10% 1
• Hip fracture risk ≤1% 1

Critical Adjustments for Glucocorticoid Users

For patients on prednisone >7.5 mg/day, manually adjust the calculated FRAX scores: 1, 6, 3

• Multiply major osteoporotic fracture risk by 1.15 1, 3
• Multiply hip fracture risk by 1.2 1, 3

For example, if the calculated hip fracture risk is 2.0%, increase it to 2.4% (2.0 × 1.2). 1 This adjustment can move a patient from moderate to high risk, triggering a treatment indication. 6

Essential Clinical Pitfalls to Avoid

Do not delay treatment when a single high-risk feature is present. A prior fragility fracture, T-score ≤-2.5, or hip fracture risk ≥3% each independently justify treatment—even if the major osteoporotic fracture risk is below 20%. 2, 6, 4

Do not use FRAX in patients already receiving osteoporosis treatment. FRAX is validated only for treatment-naïve patients aged 40-90 years. 3, 5

Do not ignore the hip-specific threshold. The 3% hip fracture threshold is an independent treatment trigger that operates separately from the 20% major osteoporotic fracture threshold. 2, 6, 3

Do not forget to adjust for high-dose glucocorticoids. The standard FRAX calculation assumes prednisone 2.5-7.5 mg/day; higher doses require manual multiplication of the risk estimates. 1, 3

Screening Context (Not Treatment Thresholds)

The 2025 USPSTF guideline used a 9.3% major osteoporotic fracture probability as a screening threshold to identify which women aged 50-64 years should undergo bone density testing—this is not a treatment threshold. 1, 6 Treatment decisions still rely on the ≥20% major osteoporotic fracture or ≥3% hip fracture cutoffs. 6, 4

First-Line Treatment for Moderate-to-High Risk

Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) are the preferred initial agents for patients meeting treatment thresholds, providing approximately 48-51% reduction in vertebral and hip fractures. 2 Denosumab is appropriate for patients with renal impairment (creatinine clearance <60 mL/min) or gastrointestinal intolerance to oral bisphosphonates. 2